옵션 체인은 다양한 행사가격과 만기일에 대한 MSP Recovery의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 MSP Recovery에 대한 시장 심리를 평가합니다..

MSP Recovery (NASDAQ:MSPR) 주식, 옵션 체인

MSP Recovery

MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery Inc

William Blair analyst Jason Ader upgrades CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) from Market Perform to Outperform.

News

Upgrades

Analyst Ratings

CVLT

William Blair Upgrades CommVault Systems to Outperform

Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) reported quarterly earnings of $1.20 per share which missed the analyst consensus estimate of $1.49 by 19.46 percent. This is a 45.95 percent decrease over earnings of $2.22 per share from the same period last year. The company reported quarterly sales of $66.28 billion which missed the analyst consensus estimate of $71.82 billion by 7.71 percent. This is a 15.81 percent decrease over sales of $78.73 billion the same period last year.

Earnings

Earnings Misses

SHEL

UPDATE: Shell Q4 Adj EPS $1.20 Misses $1.49 Estimate, Sales $66.28B Miss $71.82B Estimate

Tech

AMBA

GAUZ

Gauzy Partners With Ambarella To Deploy AI In Advanced Driver Assistance Systems (ADAS)

Seaport Global analyst Martin Englert initiates coverage on Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) with a Buy rating and announces Price Target of $55.

Price Target

Initiation

Seaport Global Initiates Coverage On Worthington Enterprises with Buy Rating, Announces Price Target of $55

Jefferies analyst Kaumil Gajrawala upgrades Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) from Hold to Buy and raises the price target from $69 to $75.

Jefferies Upgrades Coca-Cola to Buy, Raises Price Target to $75

RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Wednesday.</a>
Yesterday, the company reported fourth quarter results. Net sales increased&nbsp;9%&nbsp;year-over-year to&nbsp;$21.623 billion, beating the consensus of&nbsp;$20.535 billion. Adjusted EPS grew&nbsp;19%&nbsp;Y/Y to&nbsp;$1.54,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43268081/raytheon-collins-aerospace-drive-rtxs-strong-q4-growth-adjusted-eps-up-19" rel="noreferrer noopener">above the consensus of&nbsp;$1.38.</a>
Here are the <a target="_blank" href="https://www.benzinga.com/quote/RTX/analyst-ratings" rel="noreferrer noopener">analysts&#8217; takes on the stock</a>:
<ul>
<li>BofA Securities reiterated the Buy rating on the stock, with a price forecast of 145.</li>
<li>RBC Capital Markets analyst Ken Herbert reiterated the Outperform rating on the stock, raising the price forecast to $150 from $140.</li>
</ul>
BofA Securities: The analysts write that RTX will enter 2025 with strong demand with a backlog of $218 billion.
According to the analysts, the market will favorably view the results and 2025 margin improvement, offsetting concerns about the softer revenue growth outlook.
Overall, analysts note that RTX is a beneficiary of the current commercial aerospace cycle and strong defense demand environment.
Also Read: <a target="_blank" href="http://benzinga.com/trading-ideas/movers/25/01/43311376/alibaba-ups-ai-game-says-its-qwen2-5-max-beats-deepseek-and-openai-in-performance" rel="noreferrer noopener">Alibaba Ups AI Game, Says Its Qwen2.5 Max Beats DeepSeek and OpenAI In Performance</a>
RBC Capital Markets: Herbert notes that investors will view the RTX portfolio favorably, even as headline risk around defense increases.
The analyst highlights that Pratt &amp; Whitney&#8217;s strong pricing and volume boosted the fourth quarter results, with GTF engine pricing expected to stay strong.
Herbert adds that the engine aftermarket remains tight, benefiting pricing. The analyst projects 14% growth in GTF engine shipments and improved segment margins in 2025.
Free cash flow estimates for 2025 and 2026 are adjusted, with potential for sentiment improvement and execution driving further gains.
Price Action: RTX shares closed at $125.13 on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43285369/asml-lam-research-and-kla-lead-semicap-growth-as-ai-and-tech-upgrades-drive-105-billion-market-outlook" target="_blank" rel="noreferrer noopener">DeepSeek Sell-off Offers Opportunities On Semicaps, Analyst Bumps Up Price Forecasts For KLA, Nova And Camtek</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Equities

Reiteration

Markets

Trading Ideas

General

RTX's Strong Backlog And Pricing Power Offset Defense Risks, Analysts Forecast Big 2025 Upside

Jefferies analyst Michael Yee downgrades Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) from Buy to Hold and lowers the price target from $32 to $3.

Downgrades

CRGX

Jefferies Downgrades Cargo Therapeutics to Hold, Lowers Price Target to $3

Jefferies analyst Samad Samana maintains Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) with a Hold and raises the price target from $290 to $305.

Jefferies Maintains Hold on Automatic Data Processing, Raises Price Target to $305

Chardan Capital analyst Geulah Livshits downgrades Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) from Buy to Neutral.

Chardan Capital Downgrades Cargo Therapeutics to Neutral

Goldman Sachs analyst Kate McShane maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Neutral and raises the price target from $170 to $224.

Goldman Sachs Maintains Neutral on Williams-Sonoma, Raises Price Target to $224

Earnings Beats

CHKP

Check Point Software Q4 2024 Adj. EPS $2.70 Beats $2.66 Estimate, Sales $703.700M Beat $698.820M Estimate

Macro Economic Events

Econ #s

Economics

Eurozone Unemployment Rate For December 6.3% Vs. 6.3% Est.; 6.2% (Revised) Prior

Eurozone Gross Domestic Product (YoY) Preliminary For Q4 0.9% Vs. 1.0% Est.; 0.9% Prior

Eurozone Gross Domestic Product (QoQ) Preliminary For Q4 0.0% Vs. 0.1% Est.; 0.4% Prior

Goldman Sachs analyst Kate McShane downgrades Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) from Neutral to Sell and maintains the price target from $79 to $79.

Goldman Sachs Downgrades Floor & Decor Hldgs to Sell, Maintains Price Target to $79

Shares of Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/social-media/25/01/43322201/meta-platforms-q4-earnings-revenue-beat-eps-beat-daily-actives-up-5-continued-strong-revenue-growth-expected">fourth-quarter sales results</a>.
Meta reported fourth-quarter revenue of $48.39 billion, beating analyst estimates of $47.03 billion. The company reported fourth-quarter earnings of $8.02 per share, beating analyst estimates of $6.77 per share.
Meta shares gained 2.2% to $691.66 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Alterity Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) gained 105% to $6.13 in pre-market trading.</li>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) rose 54.1% to $0.5853 in pre-market trading.</li>
<li>X4 Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) gained 40.1% to $1.03 in pre-market trading after jumping more than 52% on Wednesday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 21.9% to $0.1240 in pre-market trading after dipping over 38% on Wednesday.</li>
<li>Carisma Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) gained 18.4% to $0.5980 in pre-market trading.</li>
<li>Alta Equipment Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) rose 14.1% to $8.01 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares jumped 13.1% to $113.66 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Ranger Energy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) gained 10.5% to $19.00 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 2.9% to $400.23 in pre-market trading. Tesla reported weaker-than-expected fourth-quarter earnings and sales results. The company, meanwhile, said it expects its vehicle business to return to growth in 2025. Tesla also promised to launch new and &#8220;more affordable&#8221; models in the first half of 2025, in addition to other promises regarding the deployment of autonomous vehicles and licensing of the company&#8217;s full self-driving (FSD) driver assistance software to rivals.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares fell 74.3% to $3.39 in pre-market trading after the company announced it discontinued its FIRCE-1 Phase 2 study.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) dipped 46.6% to $8.00 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 32.4% to $2.12 in pre-market trading. Silexion Therapeutics announced exercise of warrants for $3.3 million gross proceeds.</li>
<li>Avalon Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWX#NYSE">AWX</a>) fell 19.2% to $2.90 in today's pre-market trading.</li>
<li>Coincheck Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) shares dipped 17.1% to $7.00 in pre-market trading after falling 4% on Wednesday.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares tumbled 12.2% to $11.94 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 following the close of regular trading on Thursday, Feb. 6.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) fell 10.6% to $116.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and issued FY25 guidance below estimates.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) fell 9.4% to $1,035.79 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) declined 9.1% to $17.01 in pre-market trading. Orthofix Medical will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, before the opening bell.</li>
<li>First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) fell 6.8% to $41.00 in pre-market trading following fourth-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

A day after Elon Musk <a href="https://www.benzinga.com/markets/equities/25/01/43295163/elon-musk-says-unsupervised-full-self-driving-begins-as-tesla-can-now-drive-itself-from-factory-to-loading-docks">touted a breakthrough</a> in Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) full self-driving technology, the company&#8217;s vision-only approach to autonomous driving came under renewed scrutiny on Wednesday. Prominent investor Ross Gerber pointed out its limitations in handling different environmental conditions.
What Happened: Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, noted on X that his Tesla&#8217;s Full Self-Driving system becomes ineffective when dust or ash interferes with the cameras, or when dealing with sun glare. 
&#8220;My Tesla FSD doesn't work when dust or ash get in the cameras,&#8221; Gerber said.
His comments come at a crucial time for Tesla&#8217;s autonomous driving ambitions, as the company recently announced its vehicles can now navigate autonomously from factory to loading docks without human intervention.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My Tesla FSD doesn't work when dust or ash get in the cameras. Vision only systems have some big limitations. Also, sun shines into them wrong. Etc. doesn't work. This can only be rectified one way… <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1884616509659791589?ref_src=twsrc%5Etfw">January 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/01/43325888/tesla-likely-to-sell-optimus-to-rival-companies-in-2026-price-point-of-humanoid-robot-to-be-detemined-by-demand-says-ceo-elon-musk">Tesla Likely To Sell Optimus To Rivals In 2026, Elon Musk Says Revenue Potential Of Bot North Of $10 Trillion: &#8216;It&#8217;s Real Bananas&#8217;</a>
Why It Matters: The debate over Tesla&#8217;s camera-only approach has intensified following CEO Elon Musk&#8216;s recent defense of the strategy during the company&#8217;s <a href="https://www.benzinga.com/25/01/43327837/tesla-ceo-elon-musk-dismises-lidar-again-says-if-humans-drive-without-shooting-lasers-from-their-eyes-so-can-autonomous-cars">fourth-quarter earnings call</a>. 
&#8220;Obviously, humans drive without shooting lasers out of their eyes&#8230; humans drive with eyes and a neural net and a brain,&#8221; Musk stated, reaffirming his stance against LiDAR technology.
This discussion emerges as Tesla faces <a href="https://www.benzinga.com/25/01/42840097/nhtsa-opens-probe-into-26-million-tesla-vehicles-after-complaint-of-crash-involving-actually-smart-summon-feature">increased regulatory scrutiny</a>, with the National Highway Traffic Safety Administration launching a probe into 2.6 million Tesla vehicles equipped with FSD technology. Despite these challenges, Tesla remains optimistic about its autonomous driving future, with Musk <a href="https://www.benzinga.com/25/01/42894743/tesla-ceo-elon-musk-says-fsd-will-be-safer-than-human-drivers-in-q2-2025">predicting FSD will surpass human driving safety</a> by the second quarter of 2025.
The controversy comes as Tesla reported mixed fourth-quarter results, with revenue of $25.71 billion missing analyst estimates. The company maintains that 2025 will be a &#8220;seminal year&#8221; for <a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year">its FSD development</a>, though critics like Zoox co-founder Jesse Levinson argue that additional hardware beyond cameras is necessary for truly <a href="https://www.benzinga.com/news/24/10/41645383/elon-musk-slams-zoox-co-founder-over-fsd-criticism-your-company-would-be-dead-already-if-not-for-ama">safe autonomous operation</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43328465/no-survivors-yet-to-plane-crash-near-reagan-national-airport-american-airlines-ceo-heads-to-washington">No Survivors Yet In Plane Crash Near Reagan National Airport: American Airlines CEO Heads To Washington</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

A Day After Elon Musk Hailed Tesla's 'Unsupervised' FSD, Ross Gerber Criticizes EV Maker's Autonomous Driving System: 'Doesn't Work When Dust Or Ash Get In The Cameras'

Germany Gross Domestic Product (YoY) Preliminary For Q4	-0.2% Vs. 0.0% Est.; -0.3% Prior

Germany Gross Domestic Product (QoQ) Preliminary For Q4 -0.2% Vs. -0.1% Est.; 0.1% Prior

Goldman Sachs analyst Kate McShane upgrades RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Sell to Neutral and raises the price target from $261 to $374.

Goldman Sachs Upgrades RH to Neutral, Raises Price Target to $374

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Comments

MSP Recovery

MSP Recovery (MSPR) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌